Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Business Wire 11 days ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 28, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 19, 2024

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Business Wire February 28, 2024

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Business Wire February 27, 2024

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Business Wire February 26, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 17, 2024

Seres Therapeutics Announces VOWST(TM) Commercial Launch Update and US FDA Fast Track Designation for SER-155

Business Wire January 9, 2024

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2024

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Business Wire December 7, 2023

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

Business Wire November 28, 2023

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

PR Newswire November 21, 2023

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST(TM) Net Sales of $7.6 Million

Business Wire November 2, 2023

Flagship Pioneering Launches Pioneering Intelligence

PR Newswire November 1, 2023

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

Business Wire October 30, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 6, 2023

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

PR Newswire September 11, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 8, 2023

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Business Wire September 7, 2023

Invaio achieves first registration for citrus greening solution featuring Trecise(TM) technology

PR Newswire August 29, 2023